Securities code: Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) securities abbreviation: Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) Announcement No.: 2022011 bond Code: 113585 bond abbreviation: Shouxian convertible bond
Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896)
Special report on the deposit and actual use of raised funds in 2021
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
According to the requirements of China Securities Regulatory Commission (hereinafter referred to as “CSRC Notice No. 1 – Guidelines for the use of listed companies”) and the “guidelines for the supervision and administration of listed companies of Shanghai Stock Exchange – No. 2” and the relevant provisions of China Securities Regulatory Commission (hereinafter referred to as “CSRC Notice No. 1 – Guidelines for the use of listed companies”), The deposit and use of the raised funds of Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) (hereinafter referred to as “the company” or ” Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) “) in 2021 are described as follows:
1、 Basic information of raised funds
(I) funds raised from initial public offering
1. Actual amount of raised funds and time of fund arrival
Approved by the reply on approving Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) initial public offering of shares (zjxk [2017] No. 520) of China Securities Regulatory Commission, the company issued 34950000 ordinary shares in RMB for the initial public offering, and the total amount of funds raised was 40332300000 yuan. After deducting the new share issuance expenses paid by the company for this stock issuance, the total amount of funds raised was 451 Shanghai Pudong Development Bank Co.Ltd(600000) 0 yuan, and the net amount of funds raised was 35816300000 yuan. All the above-mentioned raised funds were in place on May 4, 2017 and deposited in the special account for raised funds. Lixin Certified Public Accountants (special general partnership) verified the availability of funds for the company’s initial public offering and issued the capital verification report (xksbz [2017] No. zf10516).
2. Use and balance of raised funds
In 2017, the company actually used the raised funds of 10678511314 yuan, the net amount of accumulated bank deposit interest minus bank handling charges was 45124758 yuan, and the income from cash management with temporarily idle raised funds was 462517059 yuan.
In 2018, the company actually used 11656507818 yuan of raised funds, received 29445103 yuan of bank deposit interest net of handling charges, and obtained 789092566 yuan of income from cash management with temporarily idle raised funds.
In 2019, the company actually used the raised funds of Shaanxi Broadcast & Tv Network Intermediary(Group)Co.Ltd(600831) 4611 yuan, and the net amount of interest received from bank deposits after deducting handling charges was 14374385 yuan. The company used the temporarily idle raised funds for cash management and obtained a profit of 482296877 yuan. As of December 31, 2019, the balance of raised funds was 9295817005 yuan, of which the balance of cash management with temporarily idle raised funds was 7850000000 yuan.
In 2020, the company actually used the raised funds of 5341640473 yuan, the accumulated net amount of interest received from bank deposits after deducting handling charges was 12306561 yuan, and the income from cash management with temporarily idle raised funds was 264011728 yuan. As of December 31, 2020, the balance of raised funds was 5975527355 yuan, of which the balance of cash management with temporarily idle raised funds was 5770000000 yuan.
In 2021, the company actually used 6173842687 yuan of raised funds, and the accumulated net amount of bank deposit interest deducting handling charges was 198315332 yuan. In this year, the company did not use idle raised funds to purchase financial products. As of December 31, 2021, the balance of raised funds was 0.00 yuan.
(II) funds raised by public issuance of convertible corporate bonds
1. Actual amount of raised funds and time of fund arrival
Approved by the reply on approving Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) public issuance of convertible corporate bonds (zjxk [2020] No. 658) of China Securities Regulatory Commission, the total amount of public issuance of the company is RMB
360 million yuan convertible corporate bonds with a face value of 100 yuan each, a total of 36 million, with a term of 6 years. After deducting the issuance expenses paid by the company for the convertible corporate bonds, the net amount of funds actually raised was 34915566038 yuan.
All the above-mentioned raised funds have been put in place on June 15, 2020 and deposited in the special account for raised funds for management. Lixin Certified Public Accountants (special general partnership) has verified the receipt of raised funds and issued the capital verification report on the paid in subscription funds (xksbz [2020] No. zf10574). The company adopts a special account storage system for the raised funds and has established relevant special accounts for the raised funds. After the raised funds are received, they have been deposited in the special account for the raised funds, and a supervision agreement has been signed with the sponsor and the bank storing the raised funds.
2. Use and balance of raised funds
In 2020, the company actually used the raised funds of 341400672 yuan, and the accumulated net amount of bank deposit interest deducting handling charges was 10802370 yuan. The company used the temporarily idle raised funds for cash management to obtain income of 122272694 yuan. As of December 31, 2020, the balance of raised funds was 34930899952 yuan, of which the balance of cash management with temporarily idle raised funds was 34000000000 yuan.
In 2021, the company actually used the raised funds of 7137046807 yuan, and the accumulated net amount of bank deposit interest deducting handling charges was 1397049988 yuan. The company used the temporarily idle raised funds for cash management and obtained financial management income of 104814110 yuan. As of December 31, 2021, the balance of raised funds is
29295717243 yuan, including 26400000000 yuan of cash management with temporarily idle raised funds and 2895717243 yuan of special account for raised funds.
2、 Management of raised funds
According to the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the Listing Rules of Shanghai Stock Exchange, the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds of listed companies (revised in 2022), the guidelines for the self-discipline supervision of listed companies of Shanghai Stock Exchange No. 1 – standardized operation and other relevant provisions.
The company stores and uses the raised funds in strict accordance with the raised funds management system, and there is no violation of the raised funds management.
(I) funds raised from initial public offering
1. On April 19, 2017, the company and Bank Of China Limited(601988) Wuyi County sub branch (hereinafter referred to as ” Bank Of China Limited(601988) Wuyi sub branch”), China Citic Bank Corporation Limited(601998) Hangzhou Branch (hereinafter referred to as ” China Citic Bank Corporation Limited(601998) Hangzhou branch”), Industrial And Commercial Bank Of China Limited(601398) Wuyi sub branch (hereinafter referred to as ” Industrial And Commercial Bank Of China Limited(601398) Wuyi sub branch”) China Merchants Bank Co.Ltd(600036) Jinhua Branch (hereinafter referred to as ” China Merchants Bank Co.Ltd(600036) Jinhua Branch”) and the sponsor Guosen Securities Co.Ltd(002736) (hereinafter referred to as ” Guosen Securities Co.Ltd(002736) “) signed the tripartite supervision agreement on the storage of special account for raised funds;
2. On May 17, 2017, the account opened by the company in China Merchants Bank Co.Ltd(600036) Jinhua Branch was
579900719110902’s special account for raised funds has been fully disbursed and cancelled on May 18, 2017, and the tripartite supervision agreement on the storage of special account for raised funds signed by the company with China Merchants Bank Co.Ltd(600036) Jinhua Branch and Guosen Securities Co.Ltd(002736) Jinhua Branch has been terminated accordingly;
3. On May 24, 2017, the company, Wuyi Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) traditional Chinese medicine decoction pieces Co., Ltd. (hereinafter referred to as ” Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) decoction pieces”), China Citic Bank Corporation Limited(601998) Hangzhou branch and the sponsor Guosen Securities Co.Ltd(002736) signed the four party supervision agreement on the storage of raised funds.
4. On December 4, 2019, the funds of the special account for raised funds opened by the company in Bank Of China Limited(601988) Wuyi sub branch with account number 357172714656 have been fully disbursed and cancelled on December 4, 2019. The tripartite supervision agreement on the storage of special account for raised funds signed by the company with Bank Of China Limited(601988) Wuyi sub branch and Guosen Securities Co.Ltd(002736) Wuyi sub branch has been terminated accordingly; 5. On December 6, 2019, the account opened by the company in China Citic Bank Corporation Limited(601998) Hangzhou branch was
The funds of 8110801014001106117 special account for raised funds have been fully disbursed and cancelled on December 6, 2019, and the tripartite supervision agreement on the storage of special account for raised funds signed by the company with China Citic Bank Corporation Limited(601998) Hangzhou branch and Guosen Securities Co.Ltd(002736) Hangzhou branch has been terminated accordingly;
6. On June 22, 2020, the account opened by the company in Industrial And Commercial Bank Of China Limited(601398) Wuyi sub branch was
120806 Harbin Medisan Pharmaceutical Co.Ltd(002900) 0458732 funds in the special account for raised funds have been fully disbursed and cancelled on June 22, 2020, and the tripartite supervision agreement on the storage of special account for raised funds signed by the company with Industrial And Commercial Bank Of China Limited(601398) Wuyi sub branch and Guosen Securities Co.Ltd(002736) Wuyi sub branch has been terminated accordingly;
7. On December 31, 2021, the funds of the special account for raised funds opened by the company in China Citic Bank Corporation Limited(601998) Hangzhou branch with account No. 8110801013101141208 have been fully spent and cancelled on December 31, 2021. The tripartite supervision agreement on the storage of special account for raised funds signed by the company with China Citic Bank Corporation Limited(601998) Hangzhou branch and Guosen Securities Co.Ltd(002736) Hangzhou branch has been terminated accordingly.
There is no significant difference between the main contents of the above three-party supervision agreement on the storage of special raised funds account and the four party supervision agreement on the storage of special raised funds account and the three-party supervision agreement (model) on the storage of special raised funds account of Shanghai Stock Exchange. The company has strictly implemented the above supervision agreement.
As of December 31, 2021, the special accounts for the funds raised by the initial public offering of shares have been cancelled. (II) funds raised by public issuance of convertible corporate bonds
The fund raising agreement of Wuyi sub branch (hereinafter referred to as “Wuyi sub branch”) was signed on June 6, 2020; On June 16, 2020, the company, Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) Yinpian, Industrial And Commercial Bank Of China Limited(601398) Wuyi sub branch and Guosen Securities Co.Ltd(002736) jointly signed the four party supervision agreement on raising funds; On June 16, 2020, the company and its wholly-owned subsidiary Jinhua Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) Pharmaceutical Co., Ltd. (hereinafter referred to as ” Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) pharmaceutical”), Bank Of China Limited(601988) Wuyi sub branch, Guosen Securities Co.Ltd(002736) jointly signed the four party supervision agreement on raising funds.
There is no significant difference in the tripartite supervision agreement (model) on the storage of raised funds in the special account formulated by the stock exchange. As of December 31, 2021, the specific deposits of the company’s raised funds are as follows:
Bank account balance of deposit bank (yuan)
China Construction Bank Corporation(601939) Wuyi sub branch 330501677327 Shenzhen China Bicycle Company (Holdings) Limited(000017) 455184.62
Industrial And Commercial Bank Of China Limited(601398) Wuyi sub branch 120806 Harbin Medisan Pharmaceutical Co.Ltd(002900) 051511719 Jiangmen Kanhoo Industry Co.Ltd(300340) 04
Bank Of China Limited(601988) Wuyi sub branch 388378066721965164777
Total / 2895717243
3、 Actual use of raised funds during the reporting period
(I) funds raised from initial public offering
1. Use of funds for projects invested with raised funds (hereinafter referred to as “projects invested with raised funds”)
During the reporting period, the actual use of the funds of the company’s projects invested by raising funds is detailed in Annex 1 comparison table of the use of funds raised by initial public offering in Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) 2021.
2. Advance investment and replacement of raised investment projects
During the reporting period, the company did not use the raised funds to replace the self raised funds invested in the raised investment projects in advance. 3. Temporary replenishment of working capital with idle raised funds
During the reporting period, the company did not use idle raised funds to temporarily supplement working capital.
4. Cash management using temporarily idle raised funds
On April 27, 2021, the 23rd Meeting of the third board of directors and the 18th meeting of the third board of supervisors respectively deliberated and approved the proposal on using some temporarily idle raised funds and self owned funds for cash management, and agreed that the company would use no more than 400 million yuan of temporarily idle raised funds and no more than 500 million yuan of temporarily idle self owned funds to buy financial products with high safety, good liquidity and low risk, The service life shall not exceed 12 months, and the resolution shall be valid within 12 months from the date of deliberation and adoption. Within the validity period of the above quota and resolution, it can be recycled and used.
As of December 31, 2021, the company used the temporarily idle funds raised from IPO for cash management, and the balance was RMB 0.00.
5. Permanent replenishment of working capital or repayment of bank loans with over raised funds
During the reporting period, the company did not use over raised funds to permanently supplement working capital or repay bank loans. 6. Over raised funds are used for projects under construction and new projects (including
